Experienced in Essential Thrombocythemia

Dr. Jeremy M. Pantin

Hematology Oncology | Hematology | Oncology
Tristar Bone Marrow Transplant, LLC
322 Hospital Blvd, 
Jackson, TN 
Accepting New Patients
21 Years of Experience
Experienced in Essential Thrombocythemia
Tristar Bone Marrow Transplant, LLC
322 Hospital Blvd, 
Jackson, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeremy Pantin is a Hematologist Oncology specialist and a Hematologist in Jackson, Tennessee. Dr. Pantin has been practicing medicine for over 21 years and is rated as an Experienced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Pantin is currently accepting new patients.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Essential Thrombocythemia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in GA
Hospital Affiliations
Tristar Centennial Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

TRISTAR BONE MARROW TRANSPLANT, LLC
322 Hospital Blvd, Jackson, TN 38305
Other Locations
TRISTAR BONE MARROW TRANSPLANT, LLC
2410 Patterson St, Suite 500, Nashville, TN 37203
TRISTAR BONE MARROW TRANSPLANT, LLC
1325 Andrea St, Suite 201, Bowling Green, KY 42104
TRISTAR BONE MARROW TRANSPLANT, LLC
2300 Patterson St, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Drug: Allogeneic NKG2D-Targeted CAR-Natural Killer T Cells
Study Phase: Phase 1
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)
An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)
Enrollment Status: Terminated
Publish Date: August 28, 2023
Intervention Type: Drug
Study Phase: Phase 1
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Ph 1 Study of Escalating Single & Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T Cells) Administered to Adult Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 18, 2023
Intervention Type: Biological
Study Drug: Mana 312
Study Phase: Phase 1
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

23 Total Publications

Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring.
Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring.
Journal: JCO oncology practice
Published: April 18, 2025
Similar Doctors
Distinguished in Essential Thrombocythemia
Dr. Archie W. Wright
Hematology Oncology | Hematology | Oncology
Distinguished in Essential Thrombocythemia
Dr. Archie W. Wright
Hematology Oncology | Hematology | Oncology

Jackson-Madison County General Hospital

650 Nuckolls Rd, 
Bolivar, TN 
 (29.9 miles away)
731-541-6834
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Archie Wright is a Hematologist Oncology specialist and a Hematologist in Bolivar, Tennessee. Dr. Wright is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lynch Syndrome, and Colorectal Cancer. Dr. Wright is currently accepting new patients.

Distinguished in Essential Thrombocythemia
Dr. Joseph E. Fouche
Oncology | Hematology
Distinguished in Essential Thrombocythemia
Dr. Joseph E. Fouche
Oncology | Hematology

Jackson-Madison County General Hospital

620 Skyline Dr, 
Jackson, TN 
 (3.2 miles away)
731-541-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Fouche is an Oncologist and a Hematologist in Jackson, Tennessee. Dr. Fouche is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Non-Hodgkin Lymphoma. Dr. Fouche is currently accepting new patients.

Advanced in Essential Thrombocythemia
Dr. Arnel Pallera
Hematology | Oncology
Advanced in Essential Thrombocythemia
Dr. Arnel Pallera
Hematology | Oncology

The West Clinic, PLLC

240 Grandview Dr, 
Brighton, TN 
 (52.2 miles away)
901-475-0678
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arnel Pallera is a Hematologist and an Oncologist in Brighton, Tennessee. Dr. Pallera is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Melanoma of the Eye, Non-Hodgkin Lymphoma, Familial Colorectal Cancer, Metastatic Uveal Melanoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pantin's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 19 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile